Corcept Therapeutics (NASDAQ: CORT) and Bioblast Pharma (NASDAQ:ORPN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This table compares Corcept Therapeutics and Bioblast Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
76.5% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 3.5% of Bioblast Pharma shares are owned by institutional investors. 15.0% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Corcept Therapeutics and Bioblast Pharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Corcept Therapeutics presently has a consensus target price of $26.40, indicating a potential upside of 41.18%. Given Corcept Therapeutics’ higher probable upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Bioblast Pharma.
Earnings & Valuation
This table compares Corcept Therapeutics and Bioblast Pharma’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corcept Therapeutics||$159.20 million||13.54||$129.12 million||$0.44||42.50|
|Bioblast Pharma||N/A||N/A||-$5.94 million||N/A||N/A|
Corcept Therapeutics has higher revenue and earnings than Bioblast Pharma.
Volatility & Risk
Corcept Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
Corcept Therapeutics beats Bioblast Pharma on 10 of the 10 factors compared between the two stocks.
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
About Bioblast Pharma
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.